Navigation Links
CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of,Action for Ranexa

-- New Preclinical Information May Correlate with Clinical HbA1c Reductions Observed in Phase 3 CARISA and MERLIN TIMI-36 Clinical Trials --

PALO ALTO, Calif., July 9, 2007 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. announced today that researchers have completed preliminary preclinical studies showing that ranolazine increased glucose stimulated insulin secretion in pancreatic beta cells. In separate experiments using preclinical models of insulin resistance, ranolazine also improved glucose homeostasis.

These data could illustrate an underlying first in class mechanism of action for the statistically significant reductions in HbA1c levels observed with Ranexa in cardiovascular patients with diabetes from the phase 3 CARISA (n=189 with angina and diabetes) and MERLIN TIMI-36 (n=2,220 with acute coronary syndromes and diabetes) clinical trials.

In CARISA (Combination Assessment of Ranolazine in Stable Angina), Ranexa (ranolazine extended release tablets) reduced HbA1c levels by an average of up to 0.7 percentage points in angina patients with diabetes. The reduction in HbA1c was not associated with increased hypoglycemia.

"Preclinical studies have shown that Ranexa inhibits the late sodium current in cardiac cells. Potentially, the sodium channels present in pancreatic beta cells may play a role in the secretion of insulin," said Luiz Belardinelli, M.D., senior vice president of pharmacological translational and biomedical research and a distinguished fellow of cardiovascular science at CV Therapeutics.

The company plans to submit data from these new preclinical experiments for publication later this year.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of ca
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
4. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
5. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
6. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
7. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
8. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
9. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
10. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
11. Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in Lamellar Ichthyosis
Post Your Comments:
(Date:8/4/2015)... , Aug. 4, 2015 Among 1,000 U.S. ... yet only half of consumers surveyed are aware of ... ever used use them, according to findings from a ... community service partnership focused on improving the health and ... online survey polled 1,000 men and women, ages 21 ...
(Date:8/3/2015)... Aug. 4, 2015   The Intellectual Property ... world,s leading provider of intelligent information for businesses ... 2015 CMR Pharmaceutical R&D Factbook , the biopharmaceutical ... concerns around declines in R&D, the analysis identifies ... trillion milestone and forecasts sales to reach $1.3 ...
(Date:8/3/2015)... WARRINGTON, Pa. , Aug. 3, 2015 /PRNewswire/ ... a specialty biotechnology company focused on developing aerosolized ... a live teleconference and webcast at 8:30 a.m. Eastern ... time management will discuss the 2015 second quarter ... The company will issue a press release announcing ...
Breaking Medicine Technology:New Study Finds Consumers are Leaving Money at the Pharmacy 2New Study Finds Consumers are Leaving Money at the Pharmacy 3Pharma Sales to Grow Beyond $1 Trillion 2Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015 Financial Results and Other Business Updates 2
... Perceptive Informatics, the industry,s leading eClinical solutions provider ... PRXL ), today announced the results ... entitled "Optimizing Adaptive Trial Designs: Using Simulation ... by Perceptive Informatics with partner Cytel Inc., a ...
... Pharmaceuticals announced today positive results from its clinical ... Prednisporin(TM) (FOV1101) in patients with persistent allergic conjunctivitis.Prednisporin(TM) ... profile (no increase in intra-ocular pressure) than PredForte(TM), ... dose of prednisolone acetate, in patients treated for ...
Cached Medicine Technology:Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs 2Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs 3Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs 4Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs 5Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis 2Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis 3
(Date:8/4/2015)... ... August 04, 2015 , ... ... an automatic end to driving, says the August 2015 Harvard Health Letter. , ... to drive. It requires an individual assessment of skills," says Lissa Kapust, a ...
(Date:8/4/2015)... ... 2015 , ... Updated enrollment data on the top U.S. health plans, as ... at http://www.AISHealth.com . The data is free to all registered users to AISHealth.com. ... charts on the website’s “Data” section include:, , Top 25 ...
(Date:8/4/2015)... ... August 04, 2015 , ... The results of a three year clinical ... rare eye disease that progressively causes blindness, were published on June 23, 2015 in ... results of the trial, the implant, more commonly known as the “bionic eye,” is ...
(Date:8/4/2015)... Miramar Beach, FL (PRWEB) , ... August 04, 2015 , ... ... people are living with psoriatic disease and its uncomfortable symptoms such as dry, itching, ... suffer from psoriasis bounce from medication to medication before they find what’s right for ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... 20 finalists for America’s Favorite Veterinarian. The contest is put on by the ... committee from 500 nominees. Nominees were evaluated on community involvement, ethical behavior, passion ...
Breaking Medicine News(10 mins):Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2Health News:Atlantic Information Services Website Offers Up-to-Date U.S. Health Plan Enrollment Data 2Health News:“Bionic Eye” Implant for the Blind Proved Safe and Effective at the End of a Three Year Clinical Trial 2Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 2Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 3Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 2Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 3
... Increases 32% to $14.2 Million ... Sets Quarterly Record, MINNEAPOLIS, Feb. 25 ATS Medical, ... products and services, today reported financial results for the,fourth quarter ... was $14.2 million, up 32.4% from $10.7 million reported in ...
... exhalations hint at wide range of conditions , , ... that uses laser light to sample a person,s breath ... number of diseases, a U.S. study says. , This ... one day help doctors screen patients for diseases such ...
... drugs is a worry, study says, , , MONDAY, Feb. 25 ... advanced dementia are given antibiotics in the last two weeks ... is whether or not that therapy has any benefits, such ... And, of concern are the risks associated with antibiotic use, ...
... Capital Growth Planning Inc., form "MaxLife-CGP",Partners LLC., a California based ... to $100M dollars in face value, of which ... ... CALIFORNIA, Feb. 25 /PRNewswire-FirstCall/ - MaxLife Fund Corp.,(OTC:MXFD). MaxLife ...
... A sophisticated robotic dog could be a good companion ... living pet, a new Saint Louis University study suggests. ... homes interacted with Sparky, a living, medium-sized gentle mutt, ... that looks like a three-dimensional cartoon. , The most ...
... Metalsmith Michael Aram,will lend his support to another noteworthy ... doors to his flagship store on March,13th for a special ... New Delhi based charity that was,established in 1994, at a ... Foundation has committed itself to raising awareness on and,preventing the ...
Cached Medicine News:Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 2Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 3Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 4Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 5Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 6Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 7Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 8Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 9Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 10Health News:Laser Screen Detects Diseases in Breath 2Health News:Antibiotic Use in Dementia Patients Questioned 2Health News:Antibiotic Use in Dementia Patients Questioned 3Health News:MaxLife Fund Corp. and Capital Growth Planning Inc., sign a joint venture agreement 2Health News:MaxLife Fund Corp. and Capital Growth Planning Inc., sign a joint venture agreement 3Health News:Faux Fido eases loneliness in nursing home residents as well as real dog, SLU study finds 2
Swiss Watchmaker Forceps, 4" extra-long precision ground points....
BB Watchmaker Forceps, Pakistan, 4.5" fine point....
Penfield Watchmaker Forceps. Tip width 0.9 mm....
Verte-Span is the latest advancement in vertebral body replacement technology. This device allows surgeons to reconstruct and stabilize certain types of anterior column defects in the spine....
Medicine Products: